Corbus Pharmaceuticals

$1.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.64%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell CRBP and other stocks, options, and ETFs commission-free!

About CRBP

Corbus Pharmaceuticals Holdings, Inc. Common Stock, also called Corbus Pharmaceuticals, is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA. The listed name for CRBP is Corbus Pharmaceuticals Holdings, Inc. Common Stock.

CEO
Yuval Cohen
Employees
141
Headquarters
Norwood, Massachusetts
Founded
2009
Market Cap
100.84M
Price-Earnings Ratio
Dividend Yield
Average Volume
4.66M
High Today
$1.23
Low Today
$1.19
Open Price
$1.22
Volume
2.38M
52 Week High
$9.78
52 Week Low
$0.91

Collections

CRBP Earnings

-$0.52
-$0.34
-$0.15
$0.03
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like